

Reference:	FOI.9964.22
Subject:	Use of Bevacizumab
Date of Request:	3 October 2022

Requested:

1. Is bevacizumab (Avastin®) available for use in the treatment of wet age-related macular degeneration (AMD) in your health board (and/or in relation to any other eye conditions). This is an unlicensed use of the drug. In 2018, the then Health Minister said its use for wet AMD in Wales would be a decision for health boards (see attached statement).
2. If bevacizumab was available in your health for this use (and/or in relation to any other eye conditions) but this is no longer the case, please could you provide details of the date it ceased to be available and reasons behind this decision.

Response:

1. Bevacizumab is not available for the treatment of wet age-related macular degeneration (AMD) in Hywel Dda University Health Board (UHB). It may be used for an individual patient where licensed alternatives are not available or suitable to an individual patient's needs. However, this would only be considered after assessment by the Consultant. UHB governance for the use of unlicensed medicines is followed and consent gained from the patient following counselling prior to use.
2. The last recorded use of Bevacizumab within the UHB was 8 April 2019.